Business Context and Reporting Period
Company: Prana Biotechnology Limited (Note: Metadata listed "Alterity Therapeutics," but filing content confirms Prana Biotechnology Limited).
Reporting Period: Financial year ended 30 June 2015.
Business Overview: Prana is a biotechnology company developing treatments for neurodegenerative diseases, specifically Alzheimer's disease (AD) and Huntington's disease (HD). The lead drug candidate, PBT2, is a Metal-Protein Attenuating Compound (MPAC). The company also has a pipeline candidate, PBT434, for Parkinsonian movement disorders.
Key Financial Metrics
| Metric | 2015 (A$) | 2014 (A$) |
|---|---|---|
| Revenue | 176,842 | 363,775 |
| Net Loss | (5,885,069) | (13,329,239) |
| Operating Cash Flow | (10,871,074) | (13,536,223) |
| Cash and Cash Equivalents | 34,909,574 | 34,167,018 |
| Net Tangible Assets | 39,113,264 | 37,686,287 |
| Loss Per Share (Basic) | (1.17) cents | (3.11) cents |
Revenue Composition: Revenue consists entirely of interest received on bank accounts.
Other Income: A$6.3 million, primarily driven by a 45% refundable R&D tax incentive (A$6.1 million).
Material Changes vs. Prior Period
- Net Loss Reduction: The net loss decreased by 55.85% to A$5.9 million. This improvement is attributed to a decrease in R&D expenditure and a significant foreign exchange gain of A$4.7 million.
- R&D Expenses: Decreased by 17.51% to A$12.3 million. The reduction is due to the completion of Phase II studies (IMAGINE and Reach2HD) and associated manufacturing costs incurred in the prior year.
- Foreign Exchange: The Australian dollar depreciated against the US dollar by 18% in 2015, resulting in a foreign exchange gain of A$4.7 million compared to a loss of A$0.7 million in 2014.
- Share Capital: Issued capital increased to A$146.9 million (from A$140.0 million) following share issuances and option exercises.
Guidance, Outlook, Risks, and Unusual Items
Regulatory Status and Clinical Hold
In February 2015, the US FDA placed PBT2 on a Partial Clinical Hold (PCH) based on non-clinical neurotoxicology findings in a dog study. This limits the dosage for future trials. Management is preparing a robust safety package to lift the hold and advance global development.
Clinical Progress
- PBT2: Completed four Phase 1 and four Phase 2 trials. Data suggests safety and tolerability for up to two years. Exploratory data from the IMAGINE extension study showed decreased amyloid levels in a specific cohort.
- PBT434: Lead candidate for Parkinson's disease. Preclinical studies show neuroprotection. Phase 1 trials in healthy volunteers are anticipated to commence in 2016.
Liquidity and Going Concern
Management believes cash reserves of A$34.9 million are sufficient to fund operations for at least 12 months. The company expects to receive an additional A$6.5 million R&D tax refund in the following year. An "At-The-Market" (ATM) facility allows for the sale of up to US$50 million in ADSs.
Key Risks
- Regulatory Approval: Failure to lift the FDA clinical hold or obtain marketing approval.
- Clinical Trial Outcomes: Uncertainty regarding efficacy in future Phase 3 trials.
- Manufacturing: Reliance on a sole manufacturer (Dr. Reddy's) for PBT2 and a sole encapsulator (Patheon).
- Intellectual Property: Risks related to patent enforcement and expiration.
Investor Verification Checklist
- FDA Clinical Hold Status: Verify the current status of the Partial Clinical Hold on PBT2 and the timeline for lifting it.
- Cash Burn Rate: Confirm the runway of the A$34.9 million cash balance against current R&D and operational expenditures.
- Manufacturing Dependencies: Assess the risk mitigation plans regarding the sole-source manufacturers for PBT2.
- Phase 3 Trial Design: Review the design and endpoints of the upcoming Phase 3 program for Huntington's disease.
- R&D Tax Incentive: Verify the timing and certainty of the A$6.5 million receivable from the Australian Taxation Office.